Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the operating margin high or low?
The operating margin of -32.45% is 91% above its 5-year average of -364.31%, near the high end of its 5-year range (-1237.81%–49.81%).
46.55% above its 12-month average of -60.71%.
Reported quarterly operating margin; no daily interpolation. Q2 FY2026 (2026-06-30): 49.81%.
OPERATING MARGIN
-32.45%
OPERATING MARGIN AVG TTM
-60.71%
OPERATING MARGIN AVG 3Y
-500.82%
OPERATING MARGIN AVG 5Y
-364.31%
OPERATING MARGIN AVG 10Y
-344.81%
OPERATING MARGIN AVG 15Y
N/A
OPERATING MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+46.55%
CURRENT VS 3Y AVG
+93.52%
CURRENT VS 5Y AVG
+91.09%
CURRENT VS 10Y AVG
+90.59%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 786 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Liquidia Corporation
Market Cap
$2.33B
Operating Margin
-32.45%
TTM Avg
-60.71%
3Y Avg
-500.82%
5Y Avg
-364.31%
Market Cap
$2.34B
Operating Margin
-340.16%
TTM Avg
-365.34%
3Y Avg
-352.03%
5Y Avg
-361.50%
Market Cap
$2.30B
Operating Margin
24.03%
TTM Avg
25.35%
3Y Avg
27.79%
5Y Avg
25.07%
Market Cap
$2.37B
Operating Margin
42.26%
TTM Avg
35.06%
3Y Avg
13.24%
5Y Avg
-28.82%
Market Cap
$2.28B
Operating Margin
-3.63%
TTM Avg
-47.27%
3Y Avg
-10.12%
5Y Avg
11.86%
Market Cap
$2.39B
Operating Margin
-867.87%
TTM Avg
-840.98%
3Y Avg
-774.76%
5Y Avg
-1234.34%
Market Cap
$2.40B
Operating Margin
-0.74%
TTM Avg
-3.89%
3Y Avg
-12.55%
5Y Avg
-17.88%
Market Cap
$2.42B
Operating Margin
-42.22%
TTM Avg
-21.11%
3Y Avg
-21.11%
5Y Avg
-21.11%
Market Cap
$2.43B
Operating Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | OPERATING MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Liquidia Corporation (LQDA) | $2.33B | -32.45% | -60.71% | -500.82% | -364.31% |
| Nurix Therapeutics, Inc. (NRIX)vs › | $2.34B | -340.16% | -365.34% | -352.03% | -361.50% |
| Harmony Biosciences Holdings, Inc. (HRMY)vs › | $2.30B | 24.03% | 25.35% | 27.79% | 25.07% |
| ADMA Biologics, Inc. (ADMA)vs › | $2.37B | 42.26% | 35.06% | 13.24% | -28.82% |
| Maravai LifeSciences Holdings, Inc. (MRVI)vs › | $2.28B | -3.63% | -47.27% | -10.12% | 11.86% |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.39B | -867.87% | -840.98% | -774.76% | -1234.34% |
| Clover Health Investments, Corp. (CLOV)vs › | $2.40B | -0.74% | -3.89% | -12.55% | -17.88% |
| Alamar Biosciences, Inc. (ALMR)vs › | $2.42B | -42.22% | -21.11% | -21.11% | -21.11% |
| Disc Medicine, Inc. (IRON)vs › | $2.43B | 0.00% | 0.00% | 0.00% | 0.00% |
| Pharvaris N.V. (PHVS)vs › | $2.15B | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
92.5%
Operating Margin
-32.5%
Operating Margin = Operating Income / Revenue
Operating margin is the percentage of revenue remaining after operating expenses, reflecting operating efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | OPERATING MARGIN |
|---|---|
| 2026-06-30 | 49.81% |
| 2026-03-31 | 46.29% |
| 2025-12-31 | 21.50% |
| 2025-09-30 | 3.25% |
| 2025-06-30 | -424.41% |
| 2025-03-31 | -1135.42% |
| 2024-12-31 | -1237.81% |
| 2024-09-30 | -656.23% |
| 2024-06-30 | -743.29% |
| 2024-03-31 | -969.08% |
| 2023-12-31 | -583.45% |
| 2023-09-30 | -404.87% |
| 2023-06-30 | -476.91% |
| 2023-03-31 | -205.48% |
| 2022-12-31 | -121.21% |
| 2022-09-30 | -279.02% |
| 2022-06-30 | -228.94% |
| 2022-03-31 | -414.43% |
| 2021-12-31 | -353.42% |
| 2021-09-30 | -222.71% |
| 2021-06-30 | -188.21% |
| 2021-03-31 | -291.86% |
| 2020-12-31 | -2151.56% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | -72.69% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | -1716.98% |
| 2018-09-30 | -5462.10% |
| 2018-06-30 | -667.42% |
| 2018-03-31 | -958.72% |
| 2017-12-31 | -395.62% |
| 2017-09-30 | -428.19% |
| 2017-06-30 | -316.82% |
| 2017-03-31 | -412.85% |
